Moclobemide is the first of a new generation of non-hydrazine, reversible MAO-A
inhibitors useful in the treatment of depression. Moclobemide is a selective
inhibitor of MAO-A, allowing tyramine to be metabolized by MAO-B. In controlled
studies, moclobemide was clinically superior to desipramine and showed no
cholinergic or cardiovascular side-effects. A metabolite is currently under
investigation for treatment of Parkinson’s disease,.
화학적 성질
White to Off-White Solid
정의
ChEBI: A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Drug interactions
Drug interactions for the RIMAs include interaction with SSRI antidepressants, which can cause the 5-HT
syndrome. The effect of stimulant drugs, such as methylphenidate and
dextroamphetamine (used to treat ADHD), may be increased. Some over-the-counter cold and hay fever
decongestants (i.e., sympathomimetic amines) can have increased stimulant effects. Selegiline, a selective
MAO-B used for Parkinson's disease, should not be used concurrently with the RIMAs. Unlike the irreversible
MAOIs, no significant interactions with foods occur, because the selective inhibition of MAO-A does not stop
the metabolism of tyramine. The RIMAs must not be taken concurrently with a nonreversible MAOI.
